Distribution of lipoprotein associated phospholipase A2 in Czech population and its interaction with conventional cardiovascular risk
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F13%3A%230000770" target="_blank" >RIV/00064190:_____/13:#0000770 - isvavai.cz</a>
Výsledek na webu
—
DOI - Digital Object Identifier
—
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Distribution of lipoprotein associated phospholipase A2 in Czech population and its interaction with conventional cardiovascular risk
Popis výsledku v původním jazyce
INTRODUCTION: Lipoprotein associated phospholipase A2 (Lp?PLA2) represent new cardiovascular risk factor and potential treatment target. We aimed to analyze the epidemiological situation of this factor in Czech population. METHODS AND RESULTS: The studypopulation consisted from 1 962 subjects, a random samples of general population (postMONICA study), and from patients with manifest coronary or cerebrovascular disease (Czech samples of EUROASPIRE III survey). Lp?PLA2 activity was estimated using commercial kits by diaDexus Inc. in frozen samples. Increased activity (by definition, i.e. higher than195 nmol/?min/?ml) was observed in 21.1 % of sample, no apparent difference between subject with and without manifest vascular disease was found. Males showed higher Lp?PLA2 activity, than females (179.6 vs 146, resp., p less than 0.0001), while no substantial increase with age was observed. Taking Lp?PLA2 activity higher than195 as dependent variable, following independent variables entered
Název v anglickém jazyce
Distribution of lipoprotein associated phospholipase A2 in Czech population and its interaction with conventional cardiovascular risk
Popis výsledku anglicky
INTRODUCTION: Lipoprotein associated phospholipase A2 (Lp?PLA2) represent new cardiovascular risk factor and potential treatment target. We aimed to analyze the epidemiological situation of this factor in Czech population. METHODS AND RESULTS: The studypopulation consisted from 1 962 subjects, a random samples of general population (postMONICA study), and from patients with manifest coronary or cerebrovascular disease (Czech samples of EUROASPIRE III survey). Lp?PLA2 activity was estimated using commercial kits by diaDexus Inc. in frozen samples. Increased activity (by definition, i.e. higher than195 nmol/?min/?ml) was observed in 21.1 % of sample, no apparent difference between subject with and without manifest vascular disease was found. Males showed higher Lp?PLA2 activity, than females (179.6 vs 146, resp., p less than 0.0001), while no substantial increase with age was observed. Taking Lp?PLA2 activity higher than195 as dependent variable, following independent variables entered
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FA - Kardiovaskulární nemoci včetně kardiochirurgie
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Ostatní
Rok uplatnění
2013
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Vnitřní lékařství
ISSN
0042-773X
e-ISSN
—
Svazek periodika
59
Číslo periodika v rámci svazku
5
Stát vydavatele periodika
CZ - Česká republika
Počet stran výsledku
7
Strana od-do
344-351
Kód UT WoS článku
—
EID výsledku v databázi Scopus
—